Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The study will be conducted as an open label, single-dose, explorative study with patients
with histologically proven cancer and, preferably, tumor positive lesions in previously
performed nuclear medicine imaging examinations.
The investigational drug will be given as a single administration in a dose of Phase:
Phase 1